Cytovale

Cytovale is committed to improving patient care by pioneering early detection technologies that assess immune activation to accelerate the time it takes to get from triage to life-saving therapies. Cytovale is based in San Francisco and venture-backed by Norwest Venture Partners, Sands Capital, Global Health Investment Corporation (GHIC), CPP Investments, Breakout Ventures and other leading investors. For more information, visit www.cytovale.com and follow Cytovale on LinkedIn and X.